scispace - formally typeset
M

M. Elizabeth Halloran

Researcher at Fred Hutchinson Cancer Research Center

Publications -  270
Citations -  19557

M. Elizabeth Halloran is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Vaccination & Population. The author has an hindex of 56, co-authored 248 publications receiving 15685 citations. Previous affiliations of M. Elizabeth Halloran include University of Washington & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Effects of Pertussis Vaccination on Disease: Vaccine Efficacy in Reducing Clinical Severity

TL;DR: The efficacy of the pertussis vaccination in reducing disease severity was 48% (95% confidence interval, 39%-55%) among children vaccinated with 3 doses of whole-cell (67%) or acellular (32%) vaccine.
Journal ArticleDOI

Community Studies for Vaccinating Schoolchildren Against Influenza

TL;DR: A plan to vaccinate schoolchildren against flu presents an opportunity to assess risks and benefits, according to the World Health Organization.
Journal ArticleDOI

Causal Vaccine Effects on Binary Postinfection Outcomes

TL;DR: The results show that pertussis vaccination has a significant causal effect in reducing disease severity and the relations between the MLE of the causal estimand and two commonly used estimators for vaccine effects on postinfection outcomes are shown.
Journal ArticleDOI

Containing Ebola at the Source with Ring Vaccination.

TL;DR: It is found that ring vaccination can successfully contain an outbreak for values of the effective reproduction number up to 1.6, and interventions that, alongside ring vaccination, could increase the likelihood of containment are identified.
Posted ContentDOI

Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis

TL;DR: To examine how emerging variants and increased vaccination have affected transmission rates, PubMed was searched from June 18, 2021, through January 7, 2022 to obtain SAR estimates and 95%CI, disaggregated by several covariates.